An observational study in Takayasu Arteritis With Pulmonary Artery Involvement, Percutaneous Transluminal Pulmonary Angioplasty and PAH Targeted Medication, sponsored by Chinese Pulmonary Vascular Disease Research Group. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by Chinese Pulmonary Vascular Disease Research Group · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Takayasu Arteritis with a site in China — 15 open to participants now, 16 under way, 2 of them phase 3. Takayasu Arteritis · China.
Among the 26 studies in Takayasu Arteritis with a site in China, this one is the 8th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2014, is one of 11 observational ones, reaches primary completion later than 14 of the 15 other live ones, and was the 17th registered.
79 studies on the registry are indexed under Takayasu Arteritis; 33 are open to participants now.
Browse Takayasu Arteritis studies →15 of the 26 studies in Takayasu Arteritis with a site in China are open now. Recruiting first, the newest first:
Shanghai Zhongshan Hospital · Sites in China
Ages 18–65
Xuanwu Hospital, Beijing · Sites in China
Ages 18–65
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–65
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–65
Shanghai Zhongshan Hospital · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 25 Takayasu Arteritis studies recruiting now, 13 (52%) set no upper age limit and 10 (40%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is below the median of 262 across 42 observational studies indexed under Takayasu Arteritis.
Median enrollment 76 across the 15 interventional studies, 1,000 across the 11 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 26 have an industry lead sponsor. The 10 most frequent:
Chinese Pulmonary Vascular Disease Research Group is the lead sponsor of 17 studies on the registry; 11 are open to participants now.
Chinese Pulmonary Vascular Disease Research Group has 2 studies filed under Takayasu Arteritis — fewer than ten, so there is no comparison to draw.
2 of the studies in Takayasu Arteritis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03372980Beijing Institute of Heart, Lung and Blood Vessel DiseasesA Registry Study on Biomarkers of Takayasu's Arteritis (ARSBTA) | 2026-12 |
| NCT07184814China-Japan Friendship HospitalClinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 26 studies in Takayasu Arteritis with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
At baseline, FAPI and FDG are performed to evaluate the activity of takayasu arteritis with pulmonary artery involvement. FAPI is also used to predict the treatment efficacy and prognosis of takayasu arteritis with pulmonary artery involvement.
patients diagnosed with Takayasu arteries with pulmonary arteries involvement received either medical or percutaneous transluminal pulmonary angioplasty
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Percutaneous transluminal pulmonary angioplasty
all cause death
all cause death
Time frame: 2014/1/1-2042/12/31
mean pulmonary arterial pressure change
change of mean pulmonary arterial pressure after treatment
Time frame: 2014/1/1-2042/12/31
pulmonary vascular resistance change
chagne of pulmonary vascular resistance after treatment
Time frame: 2014/1/1-2042/12/31
6MWD change
change of six minute walk distance after treatment
Time frame: 2014/1/1-2042/12/31
peak VO2 change
change of peak oxygen consumption after treatment
Time frame: 2014/1/1-2042/12/31
NT-proBNP change
change of NT-proBNP after treatment
Time frame: 2014/1/1-2042/12/31
RV/LV change
change of right ventricular end-diastolic diameter versus laboratory left ventricular end-diastolic diameterafter treatment
Time frame: 2014/1/1-2042/12/31
CI change
change of cardiac index after treatment
Time frame: 2014/1/1-2042/12/31
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2014 (actual). Primary completion is estimated for Dec 2042, 347 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese Pulmonary Vascular Disease Research Group